{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:11:23Z","timestamp":1788343883828,"version":"build-2803163510"},"reference-count":25,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>von Willebrand disease (VWD) is a congenital bleeding disorder characterized by deficient or defective von Willebrand factor (VWF). Among women with VWD, postpartum hemorrhage (PPH) is common. Treatment options at delivery include plasma-derived VWF (pdVWF) and recombinant VWF (rVWF). However, limited data are available regarding their efficacy. We conducted a retrospective observational study comparing PPH in women with VWD treated at the Hemophilia Center of Western Pennsylvania between 1 February 2017 and 31 January 2018 with either rVWF or pdVWF. We compared postpartum outcomes, including PPH frequency and estimated blood loss (EBL) at delivery. There were a total of 12 deliveries, 7 vaginal and 5 cesarean. At delivery and for 3 days postpartum, 6 women received 80 IU\/kg of rVWF and 6 received 80 IU\/kg of pdVWF, based on prepregnancy weight, insurance, and\/or patient choice. Treatment groups had similar demographics, including median age (32.0 vs 27.0 years; P = .075), bleeding scores (3.0 vs 3.5; P = .734), and prepregnancy body mass index (29.0 vs 29.2 kg\/m2; P = .691). PPH occurred in 3 (25.0%) of 12 deliveries, with no difference by treatment group (2 of 6 rVWF vs 1 of 6 pdVWF; P = 1.000) and no difference in EBL by treatment group (685 vs 462 mL; P = .384) or delivery type (vaginal, P = .722 vs cesarean, P = .531). In summary, PPH occurred in one-fourth of the deliveries in women with VWD, despite a higher dose (80 IU\/kg) of rVWF or pdVWF. Future trials are needed to develop and assess novel strategies to prevent PPH in VWD.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002046","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T16:40:36Z","timestamp":1595349636000},"page":"3234-3238","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-8987","authenticated-orcid":false,"given":"Nicoletta","family":"Machin","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh PA; Division of Hematology\/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh PA; and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh PA; Division of Hematology\/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh PA; and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"issue":"21","key":"2020072111360753600_B1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2020072111360753600_B2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2516.1999.00342.x","article-title":"von Willebrand disease and bleeding in women","volume":"5","author":"Ragni","year":"1999","journal-title":"Haemophilia"},{"issue":"4","key":"2020072111360753600_B3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/hae.12635","article-title":"Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey","volume":"21","author":"Stoof","year":"2015","journal-title":"Haemophilia"},{"issue":"2","key":"2020072111360753600_B4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/01.ogx.0000197818.94002.91","article-title":"Von Willebrand disease","volume":"61","author":"James","year":"2006","journal-title":"Obstet Gynecol Surv"},{"issue":"3","key":"2020072111360753600_B5","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.ajog.2017.05.004","article-title":"The impact of postpartum hemorrhage on hospital length of stay and inpatient mortality: a National Inpatient Sample-based analysis","volume":"217","author":"Marshall","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2020072111360753600_B6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ejh.13250","article-title":"Pregnancy and delivery in women with von Willebrand disease","volume":"103","author":"Castaman","year":"2019","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020072111360753600_B7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2003-38897","article-title":"Hemostasis during normal pregnancy and puerperium","volume":"29","author":"Hellgren","year":"2003","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2020072111360753600_B8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2516.2006.01314.x","article-title":"The obstetric and gynaecological management of women with inherited bleeding disorders\u2014review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors\u2019 Organization","volume":"12","author":"Lee","year":"2006","journal-title":"Haemophilia"},{"issue":"1","key":"2020072111360753600_B9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/hae.12568","article-title":"Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis","volume":"21","author":"James","year":"2015","journal-title":"Haemophilia"},{"issue":"10","key":"2020072111360753600_B10","doi-asserted-by":"crossref","first-page":"e0164683","DOI":"10.1371\/journal.pone.0164683","article-title":"Postpartum hemorrhage in women with von Willebrand disease\u2014a retrospective observational study [published correction appears in PLoS One. 2017;12(2):e0172185]","volume":"11","author":"Govorov","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"2020072111360753600_B11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/CIRCULATIONAHA.114.009029","article-title":"Cardiovascular physiology of pregnancy","volume":"130","author":"Sanghavi","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"2020072111360753600_B12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bj\u00f6rkman","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2020072111360753600_B13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/hae.12300","article-title":"Pharmacokinetic analysis of anti-hemophilic factor in the obese patient","volume":"20","author":"Graham","year":"2014","journal-title":"Haemophilia"},{"issue":"11","key":"2020072111360753600_B14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/bloodadvances.2017005090","article-title":"Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease","volume":"1","author":"Ragni","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"2020072111360753600_B15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1055\/s-0030-1255445","article-title":"Structure and function of a recombinant von Willebrand factor drug candidate","volume":"36","author":"Turecek","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2020072111360753600_B16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","article-title":"Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial","volume":"122","author":"Mannucci","year":"2013","journal-title":"Blood"},{"key":"2020072111360753600_B17","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Safety, efficacy, and pharmacokinetics of a recombinant von Willebrand factor in patients with severe von Willebrand disease [published correction in Blood. 2016;127(22):2777]","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020072111360753600_B18","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/hae.13916","article-title":"Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease","volume":"26","author":"Trossa\u00ebrt","year":"2020","journal-title":"Haemophilia"},{"key":"2020072111360753600_B19","author":"World Health Organization","year":"2012"},{"issue":"4","key":"2020072111360753600_B20","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1097\/AOG.0000000000002351","article-title":"Practice bulletin No. 183: postpartum hemorrhage","volume":"130","author":"Committee on Practice Bulletins-Obstetrics","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"11","key":"2020072111360753600_B21","doi-asserted-by":"crossref","first-page":"e112935","DOI":"10.1371\/journal.pone.0112935","article-title":"Complex changes in von Willebrand factor-associated parameters are acquired during uncomplicated pregnancy","volume":"9","author":"Drury-Stewart","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"2020072111360753600_B22","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1038\/s41598-017-06959-6","article-title":"Platelet behaviour on von Willebrand factor changes in pregnancy: consequences of haemodilution and intrinsic changes in platelet function","volume":"7","author":"Cowman","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"2020072111360753600_B23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.V69.2.460.460","article-title":"Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors","volume":"69","author":"Kruithof","year":"1987","journal-title":"Blood"},{"issue":"9734","key":"2020072111360753600_B24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"issue":"10084","key":"2020072111360753600_B25","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial [published correction appears in Lancet. 2017;389(10084):2104]","volume":"389","author":"WOMAN trial collaborators","year":"2017","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/14\/3234\/1749238\/advancesadv2020002046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/14\/3234\/1749238\/advancesadv2020002046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T16:40:59Z","timestamp":1595349659000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/14\/3234\/461424\/Recombinant-vs-plasmaderived-von-Willebrand-factor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":25,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002046","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]}}}